NCT03671746View on ClinicalTrials.gov

Inflammatory Markers in Trauma Patient Outcomes

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

June 20, 2023

Study Completion Date

June 20, 2023

Conditions
Polytrauma
Interventions
DRUG

Ketorolac

Participants will receive Ketorolac at 15 mg IV every 6 hours for their first 5 days of hospitalization

DRUG

Saline Solution

Participants will receive 1 ml of saline solution IV every 6 hours for their first 5 days of hospitalization

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
lead

Arun Aneja

OTHER

NCT03671746 - Inflammatory Markers in Trauma Patient Outcomes | Biotech Hunter | Biotech Hunter